ZZ Biotech

Biotechnology
Clinical trials: 3No open roles listed
Data updated Nov 20, 2026Full reportReport a mistake

Facts

as of Nov 20, 2026

ZZ Biotech, LLC developed 3K3A-APC, an engineered variant of human activated protein C, and has agreed in principle to sell its 3K3A-APC dermatology program to Dermatherix Pty Ltd.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Products

Products →

ZZ Biotech has 3 clinical trials on record, 0 under way.

Clinical trials
Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke
phase 3 · stopped or withdrawn · Ischemic Stroke
Oct 2024
Safety Evaluation of 3K3A-APC in Ischemic Stroke
phase 2 · completed · 110 participants · Ischemic Stroke
Oct 2014
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC in Healthy Adult Volunteers
phase 1 · completed · 64 participants · Healthy
Aug 2012
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices